CanadaBis Capital Past Earnings Performance
Past criteria checks 4/6
CanadaBis Capital has been growing earnings at an average annual rate of 63.3%, while the Pharmaceuticals industry saw earnings growing at 26.2% annually. Revenues have been growing at an average rate of 54.8% per year. CanadaBis Capital's return on equity is 39.4%, and it has net margins of 15.6%.
Key information
63.3%
Earnings growth rate
65.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 54.8% |
| Return on equity | 39.4% |
| Net Margin | 15.6% |
| Last Earnings Update | 31 Jan 2024 |
Recent past performance updates
Recent updates
Earnings Working Against CanadaBis Capital Inc.'s (CVE:CANB) Share Price Following 48% Dive
Apr 02
If EPS Growth Is Important To You, CanadaBis Capital (CVE:CANB) Presents An Opportunity
Feb 12Is CanadaBis Capital (CVE:CANB) Using Too Much Debt?
Dec 01CanadaBis Capital (CVE:CANB) Seems To Use Debt Quite Sensibly
Jul 17CanadaBis Capital Inc.'s (CVE:CANB) Shares Climb 70% But Its Business Is Yet to Catch Up
Apr 17Auditors Have Doubts About CanadaBis Capital (CVE:CANB)
Dec 01Is CanadaBis Capital (CVE:CANB) A Risky Investment?
Aug 13Is CanadaBis Capital (CVE:CANB) Using Too Much Debt?
Apr 30Is CanadaBis Capital (CVE:CANB) Using Debt Sensibly?
Jan 13Is CanadaBis Capital (CVE:CANB) Using Too Much Debt?
Apr 07Have Insiders Been Selling CanadaBis Capital Inc. (CVE:CANB) Shares This Year?
Feb 14Here's Why CanadaBis Capital (CVE:CANB) Can Afford Some Debt
Dec 23
Revenue & Expenses BreakdownBeta
How CanadaBis Capital makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jan 24 | 21 | 3 | 7 | 0 |
| 31 Oct 23 | 23 | 4 | 7 | 0 |
| 31 Jul 23 | 22 | 4 | 7 | 0 |
| 30 Apr 23 | 22 | 4 | 6 | 0 |
| 31 Jan 23 | 18 | 3 | 5 | 0 |
| 31 Oct 22 | 15 | 2 | 5 | 0 |
| 31 Jul 22 | 12 | 1 | 4 | 0 |
| 30 Apr 22 | 9 | -1 | 5 | 0 |
| 31 Jan 22 | 8 | -1 | 5 | 0 |
| 31 Oct 21 | 8 | -2 | 5 | 0 |
| 31 Jul 21 | 7 | -3 | 4 | 0 |
| 30 Apr 21 | 9 | -2 | 4 | 0 |
| 31 Jan 21 | 7 | -2 | 4 | 0 |
| 31 Oct 20 | 6 | -3 | 4 | 0 |
| 31 Jul 20 | 4 | -5 | 6 | 0 |
| 30 Apr 20 | 1 | -10 | 8 | 0 |
| 31 Jan 20 | 0 | -13 | 8 | 0 |
| 31 Oct 19 | 0 | -12 | 7 | 0 |
| 31 Jul 19 | 0 | -9 | 5 | 0 |
| 30 Apr 19 | 0 | -5 | 1 | 0 |
| 31 Jan 19 | 0 | -1 | 1 | 0 |
| 31 Oct 18 | 0 | 0 | 0 | 0 |
| 31 Jul 18 | 0 | 0 | 0 | 0 |
Quality Earnings: CANB has a high level of non-cash earnings.
Growing Profit Margin: CANB's current net profit margins (15.6%) are higher than last year (14.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CANB has become profitable over the past 5 years, growing earnings by 63.3% per year.
Accelerating Growth: CANB's earnings growth over the past year (25.6%) is below its 5-year average (63.3% per year).
Earnings vs Industry: CANB earnings growth over the past year (25.6%) exceeded the Pharmaceuticals industry 18.4%.
Return on Equity
High ROE: CANB's Return on Equity (39.4%) is considered high.